159 related articles for article (PubMed ID: 37919902)
1. Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.
Cataldi MP; Vannoy CH; Blaeser A; Tucker JD; Leroy V; Rawls R; Killilee J; Holbrook MC; Lu QL
Mol Ther; 2023 Dec; 31(12):3478-3489. PubMed ID: 37919902
[TBL] [Abstract][Full Text] [Related]
2. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
Elife; 2021 Jan; 10():. PubMed ID: 33513091
[TBL] [Abstract][Full Text] [Related]
3. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
Cataldi MP; Lu P; Blaeser A; Lu QL
Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
[TBL] [Abstract][Full Text] [Related]
4. AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.
Gicquel E; Maizonnier N; Foltz SJ; Martin WJ; Bourg N; Svinartchouk F; Charton K; Beedle AM; Richard I
Hum Mol Genet; 2017 May; 26(10):1952-1965. PubMed ID: 28334834
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions.
Xu L; Lu PJ; Wang CH; Keramaris E; Qiao C; Xiao B; Blake DJ; Xiao X; Lu QL
Mol Ther; 2013 Oct; 21(10):1832-40. PubMed ID: 23817215
[TBL] [Abstract][Full Text] [Related]
6. [Limb-Girdle Muscular Dystrophy type R9 linked to the FKRP gene: state of the art and therapeutic perspectives].
Villar Quiles RN; Richard I; Bouchet-Seraphin C; Stojkovic T
Med Sci (Paris); 2020 Dec; 36 Hors série n° 2():28-33. PubMed ID: 33427633
[TBL] [Abstract][Full Text] [Related]
7. ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice.
Cataldi MP; Blaeser A; Lu P; Leroy V; Lu QL
Mol Ther Methods Clin Dev; 2020 Jun; 17():271-280. PubMed ID: 31988979
[TBL] [Abstract][Full Text] [Related]
8. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
Kanagawa M; Toda T
J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
[TBL] [Abstract][Full Text] [Related]
9. Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein.
Vannoy CH; Xu L; Keramaris E; Lu P; Xiao X; Lu QL
Hum Gene Ther Methods; 2014 Jun; 25(3):187-96. PubMed ID: 24635668
[TBL] [Abstract][Full Text] [Related]
10. Revertant Phenomenon in DMD and LGMD2I and Its Therapeutic Implications: A Review of Study Under Mentorship of Terrence Partridge.
Lu QL
J Neuromuscul Dis; 2021; 8(s2):S359-S367. PubMed ID: 34151854
[TBL] [Abstract][Full Text] [Related]
11. Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model.
Wu B; Drains M; Shah SN; Lu PJ; Leroy V; Killilee J; Rawls R; Tucker JD; Blaeser A; Lu QL
PLoS One; 2022; 17(12):e0278482. PubMed ID: 36454905
[TBL] [Abstract][Full Text] [Related]
12. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
[TBL] [Abstract][Full Text] [Related]
13. Cell endogenous activities of fukutin and FKRP coexist with the ribitol xylosyltransferase, TMEM5.
Nishihara R; Kobayashi K; Imae R; Tsumoto H; Manya H; Mizuno M; Kanagawa M; Endo T; Toda T
Biochem Biophys Res Commun; 2018 Mar; 497(4):1025-1030. PubMed ID: 29477842
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy.
Kuwabara N; Imae R; Manya H; Tanaka T; Mizuno M; Tsumoto H; Kanagawa M; Kobayashi K; Toda T; Senda T; Endo T; Kato R
Nat Commun; 2020 Jan; 11(1):303. PubMed ID: 31949166
[TBL] [Abstract][Full Text] [Related]
15. Fukutin-Related Protein: From Pathology to Treatments.
Ortiz-Cordero C; Azzag K; Perlingeiro RCR
Trends Cell Biol; 2021 Mar; 31(3):197-210. PubMed ID: 33272829
[TBL] [Abstract][Full Text] [Related]
16. Zebrafish models for human FKRP muscular dystrophies.
Kawahara G; Guyon JR; Nakamura Y; Kunkel LM
Hum Mol Genet; 2010 Feb; 19(4):623-33. PubMed ID: 19955119
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9 KO Cell Line Generation and Development of a Cell-Based Potency Assay for rAAV-FKRP Gene Therapy.
Geoffroy M; Pili L; Buffa V; Caroff M; Bigot A; Gicquel E; Rouby G; Richard I; Fragnoud R
Cells; 2023 Oct; 12(20):. PubMed ID: 37887288
[TBL] [Abstract][Full Text] [Related]
18. Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy.
van Tol W; van Scherpenzeel M; Alsady M; Riemersma M; Hermans E; Kragt E; Tasca G; Kamsteeg EJ; Pennings M; van Beusekom E; Vermeulen JR; van Bokhoven H; Voermans NC; Willemsen MA; Ashikov A; Lefeber DJ
Clin Chem; 2019 Oct; 65(10):1295-1306. PubMed ID: 31375477
[TBL] [Abstract][Full Text] [Related]
19. Metabolomics Analysis of Skeletal Muscles from FKRP-Deficient Mice Indicates Improvement After Gene Replacement Therapy.
Vannoy CH; Leroy V; Broniowska K; Lu QL
Sci Rep; 2019 Jul; 9(1):10070. PubMed ID: 31296900
[TBL] [Abstract][Full Text] [Related]
20. A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.
Serafini PR; Feyder MJ; Hightower RM; Garcia-Perez D; Vieira NM; Lek A; Gibbs DE; Moukha-Chafiq O; Augelli-Szafran CE; Kawahara G; Widrick JJ; Kunkel LM; Alexander MS
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
